Validating the impact of a molecular subtype in ovarian cancer on outcomes: A study of the OVCAD Consortium

Most patients with epithelial ovarian cancer (EOC) are diagnosed at advanced stage and have a poor prognosis. However, a small proportion of these patients will survive, whereas others will die very quickly. Clinicopathological factors do not allow precise identification of these subgroups. Thus, we have validated a molecular subclassification as new prognostic factor in EOC. One hundred and ninety‐four patients with Stage II–IV EOC were characterized by whole‐genome expression profiling of tumor tissues and were classified using a published 112 gene set, derived from an International Federation of Gynecology and Obstetrics (FIGO) stage‐directed supervised classification approach. The 194 tumor samples were classified into two subclasses comprising 95 (Subclass 1) and 99 (Subclass 2) tumors. All nine FIGO II tumors were grouped in Subclass 1 (P = 0.001). Subclass 2 (54% of advanced‐stage tumors) was significantly correlated with peritoneal carcinomatosis and non‐optimal debulking. Patients with Subclass 2 tumors had a worse overall survival for both serous and non‐serous histological subtypes, as revealed by univariate analysis (hazard ratios [HR] of 3.17 and 17.11, respectively; P ≤ 0.001) and in models corrected for relevant clinicopathologic parameters (HR 2.87 and 12.42, respectively; P ≤ 0.023). Significance analysis of microarrays revealed 2082 genes that were differentially expressed in advanced‐grade serous tumors of both subclasses and the focal adhesion pathway as the most deregulated pathway. In the present validation study, we have shown that, in advanced‐stage serous ovarian cancer, two approximately equally large molecular subtypes exist, independent of classical clinocopathological parameters and presenting with highly different whole‐genome expression profiles and a markedly different overall survival. Similar results were obtained in a small cohort of patients with non‐serous tumors. (Cancer Sci 2012; 103: 1334–1341)

[1]  V. Torri,et al.  Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)). , 1990, British Journal of Cancer.

[2]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[3]  Jeffrey C Miecznikowski,et al.  Comparative survival analysis of breast cancer microarray studies identifies important prognostic genetic pathways , 2010, BMC Cancer.

[4]  J. Lancaster,et al.  Microarray-based gene expression studies in ovarian cancer. , 2011, Cancer control : journal of the Moffitt Cancer Center.

[5]  C. Isella,et al.  A molecular signature for Epithelial to Mesenchymal transition in a human colon cancer cell system is revealed by large-scale microarray analysis , 2009, Clinical & Experimental Metastasis.

[6]  R. Ozols,et al.  Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Fan,et al.  Pilot Study: Alteration of Deleted in Liver Cancer1 and Phosphorylated Focal Adhesion Kinase Y397 Cytoplasmic Expression and the Prognostic Value in Advanced Epithelial Ovarian Carcinoma , 2011, International journal of molecular sciences.

[8]  D.,et al.  Regression Models and Life-Tables , 2022 .

[9]  E L Kaplan.  NON-PARAMETRIC ESTIMATION FROM INCOMPLETE OBSERVATION , 1958 .

[10]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[11]  D G Altman,et al.  A prognostic model for ovarian cancer , 2001, British Journal of Cancer.

[12]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[13]  M. Parmar,et al.  Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) , 2010, International Journal of Gynecologic Cancer.

[14]  C. Gilks,et al.  Subclassification of Ovarian Surface Epithelial Tumors Based on Correlation of Histologic and Molecular Pathologic Data , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[15]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[16]  Georg Heinze,et al.  Comparing the importance of prognostic factors in Cox and logistic regression using SAS , 2003, Comput. Methods Programs Biomed..

[17]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[18]  W. Liang,et al.  TM4 microarray software suite. , 2006, Methods in enzymology.

[19]  S. Leung,et al.  Calculator for ovarian carcinoma subtype prediction , 2011, Modern Pathology.

[20]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[21]  A. Ashworth,et al.  Breast cancer molecular profiling with single sample predictors: a retrospective analysis. , 2010, The Lancet. Oncology.

[22]  E. Venkatraman,et al.  Identification of prognostic factors in advanced epithelial ovarian carcinoma. , 2001, Gynecologic oncology.

[23]  Luigi Marchionni,et al.  Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2 , 2004, Oncogene.

[24]  Ituro Inoue,et al.  Gene expression profiling of advanced‐stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis , 2009, Cancer science.

[25]  H. Kitchener,et al.  Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: Taking Endometrial Cancer Trials Into the Translational Era , 2013, International Journal of Gynecologic Cancer.

[26]  G. Rustin,et al.  Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Liz Y. Han,et al.  Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. , 2007, Cancer research.

[28]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[29]  D. Gospodarowicz,et al.  Fibroblast growth factor , 1986, Molecular and Cellular Endocrinology.

[30]  G. Glinsky,et al.  Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. , 2005, The Journal of clinical investigation.

[31]  W. Liang,et al.  9) TM4 Microarray Software Suite , 2006 .

[32]  A. Bryant,et al.  Optimal primary surgical treatment for advanced epithelial ovarian cancer. , 2011, The Cochrane database of systematic reviews.

[33]  W. McCluggage,et al.  Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. , 2011, Pathology.